| 000 | 01689 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250513084652.0 | ||
| 264 | 0 | _c19960301 | |
| 008 | 199603s 0 0 eng d | ||
| 022 | _a0022-2623 | ||
| 024 | 7 |
_a10.1021/jm950576c _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJungheim, L N | |
| 245 | 0 | 0 |
_aPotent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands. _h[electronic resource] |
| 260 |
_bJournal of medicinal chemistry _cJan 1996 |
||
| 300 |
_a96-108 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAmino Acids _xmetabolism |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntiviral Agents _xchemical synthesis |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 |
_aCysteine _xanalogs & derivatives |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 |
_aHIV Protease _xmetabolism |
| 650 | 0 | 4 |
_aHIV Protease Inhibitors _xchemical synthesis |
| 650 | 0 | 4 |
_aHIV-1 _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLigands |
| 650 | 0 | 4 | _aMagnetic Resonance Spectroscopy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMass Spectrometry |
| 650 | 0 | 4 | _aMolecular Structure |
| 650 | 0 | 4 | _aProtein Binding |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 650 | 0 | 4 |
_aSulfones _xchemical synthesis |
| 700 | 1 | _aShepherd, T A | |
| 700 | 1 | _aBaxter, A J | |
| 700 | 1 | _aBurgess, J | |
| 700 | 1 | _aHatch, S D | |
| 700 | 1 | _aLubbehusen, P | |
| 700 | 1 | _aWiskerchen, M | |
| 700 | 1 | _aMuesing, M A | |
| 773 | 0 |
_tJournal of medicinal chemistry _gvol. 39 _gno. 1 _gp. 96-108 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1021/jm950576c _zAvailable from publisher's website |
| 999 |
_c8567904 _d8567904 |
||